Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028596 | 0.86 | ADORA2B (0.71) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5030717 | 0.84 | ADORA2B (0.49) | ADORA2BADORA2AADORA1 | |
| SCHEMBL5031570 | 0.81 | ADORA2B (0.49) | ADORA2BADORA2AADORA1 | |
| SCHEMBL5030849 | 0.81 | ADORA2A (0.65) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL4419729 | 0.81 | ADORA2B (0.64) | ADORA2BADORA2AADORA1 | |
| SCHEMBL4563476 | 0.81 | ADORA2B (0.64) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5033080 | 0.80 | ADORA2B (0.66) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5033085 | 0.79 | ADORA2B (0.62) | ADORA2BADORA2AADORA1 | |
| SCHEMBL5035042 | 0.79 | ADORA2A (0.62) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5035068 | 0.79 | ADORA2B (0.62) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7423041-B2 | e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7202252-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050119258-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119258-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885KDM4E 4460/4885 |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885KDM4E 4460/4885 |
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885KDM4E 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.